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Abstract— Aims: Disulﬁram is widely used to prevent alcoholic relapse. However, due to the intended adverse reaction with ethanol,
some believe that its use is dangerous for patients with personality disorders or psychiatric comorbidities because of their increased risk
of impulsivity or suicidal behaviour. We examined the safety and eﬃcacy in relapse prevention of a series of alcoholics with borderline
personality disorder (BPD).Methods: Case history study of patients diagnosed with BPD, prescribed disulﬁram in a dose of 1.5–2.5 g/
week, supervised by a physician in up to three brief contacts per week. Results: Two out of eight patients remained completely ab-
stinent during the supervised disulﬁram therapy over a mean period of 9.25 months. Adherence to treatment was 18.44 ± 21.78 months.
The ﬁrst relapse occurred after 1.38 ± 1.41 months. The cumulated time of abstinence was 16.88 ± 20.48 months. The overall toler-
ability was considered to be high; dizziness and fatigue appeared in all patients at the beginning of the therapy but did not persist. No
serious adverse events or ethanol–disulﬁram interactions were observed. No suicidal behaviour was reported. Conclusions: Although
case observations should be interpreted with caution, supervised disulﬁram seems to deserve further investigation in patients with
comorbid BPD, for whom it appears to help prevent alcoholic relapse.
INTRODUCTION
The eﬃcacy of pharmacological and psychosocial treatments
for relapse prevention in alcoholism has been supported in
several reviews (Berglund et al., 2003; Chick et al., 2003;
Mann, 2004; Mutschler et al., 2008a, 2008b). Currently, three
diﬀerent substances are fairly widely licensed for pharmaco-
logical alcohol relapse prevention: The NMDA receptor
modulator acamprosate, the μ-opioid antagonist naltrexone
and the acetaldehydedehydrogenase (ALDH-1 and -2) inhibi-
tor disulﬁram (Mann, 2004). Disulﬁram is an irreversible
inhibitor of ALDH-1 and ALDH-2 and increases acetaldehyde
levels during alcohol drinking (Mutschler et al., 2008a,
2008b; Arolfo et al., 2009) and is thus used as an aversive
therapeutic agent (Suh et al., 2006). Besides the inhibition
of ALDH-1 and ALDH-2, recently other possible central
modes of actions (e.g. inhibition of the dopamine beta hydrox-
ylase) of disulﬁram are discussed (Weinshenker and
Schroeder, 2007; Mutschler et al., 2008a, 2008b).
There are three published randomized controlled studies
that compared naltrexone and/or acamprosate with disulﬁ-
ram. Supervised treatment with disulﬁram appeared to be
more eﬀective in alcohol relapse prevention compared to
naltexone and acamprosate even though patients treated with
those compounds (sometimes called ‘anti-craving drugs’) re-
ported lower craving levels (de Sousa and de Sousa, 2004,
2005; Laaksonen et al., 2008; Diehl et al., 2010). However,
disulﬁram use widely varies between clinical settings partly
because of doubts about eﬃcacy and safety concerns (rare
fulminant hepatitis, and the possibility of a dangerous etha-
nol–disulﬁram reaction, caused by increased acetaldehyde
levels during alcohol drinking). Disulﬁram is sometimes as-
sumed to be more dangerous in patients with personality
disorders (especially patients with borderline personality dis-
orders, BPD) since these patients tend to be impulsive, their
self-control is reduced and they self-injure and make suicidal
threats/attempts more than patients with alcohol dependence
without concomitant psychiatric disorders (Aberg, 1984).
But there are also less logical reasons for the sparse use of
disulﬁram; for example, some therapists believe that alcohol
dependence should be treated without recourse to medica-
tion, and commentators (e.g. Brewer, 1990) have remarked
that the literature demonstrating the eﬃcacy of supervised
disulﬁram is often ignored or misinterpreted, even by medi-
cal reviewers.
The fear that patients with BPD especially could suﬀer se-
rious harm by drinking alcohol while taking disulﬁram
contributes to the common opinion that disulﬁram is not suit-
able for the treatment of alcohol addiction in patients with this
personality disorder. However, they are a group who particu-
larly tend to have poor treatment outcomes with higher rates
of relapse to alcohol and a greater likelihood for developing
alcohol-related problems (Pettinati et al., 1999; Stepp et al.,
2005; Preuss et al., 2009).
Borderline personality disorder and alcohol dependence
commonly overlap in both inpatient and outpatient settings. In
a European clinical–epidemiological study, 5.1% of the alco-
hol-dependent patients were diagnosed with BPD (Echeburúa
et al., 2007). Trull et al. (2000) found alcohol use disorders
(abuse or dependence) in 48.8% of patients suﬀering from bor-
derline personality disorder. Currently, there are few eﬀective
and speciﬁc therapeutic strategies available for these comor-
bidly aﬀected patients (Dimeﬀ and Linehan, 2008), and
evidence for any eﬀective pharmacotherapy for BPD is some-
what limited (Lieb et al., 2010).
Because disulﬁram still appears to be rarely used in patients
with borderline personality disorder and co-occurring alcohol
dependence, we set out to examine the safety and eﬃcacy of
supervised disulﬁram in alcoholics suﬀering from comorbid
BPD and seen at our service.
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METHODS
Subjects and therapy
This retrospective data collection refers to our routine outpa-
tient treatment over a period of nearly 6 years (from
December 2003 to September 2009). We located eight pa-
tients (two male, six female) attending our clinic who
fulﬁlled diagnostic criteria for alcohol dependence and
BPD according to International Classiﬁcation of Disease
(ICD)-10 and Diagnostic and Statistical Manual of Mental
Disorders (DSM)-IV. For patient details, see Tables 1 and 2.
After 3 weeks of detoxiﬁcation and combined psychothera-
peutic treatment in our inpatient department, treatment was
continued in our outpatient ‘antabuse-programme’. Disulﬁram
was uptitrated within the last week of the 3-week inpatient treat-
ment in all patients if written informed consent was provided. In
the outpatient phase, disulﬁram was given 3 days per week in
tablet form, with a total dose between 1.5 and 2.5 g/week.
In the outpatient programme, disulﬁram intake was super-
vised by a physician, establishing a therapeutic ritual with
high-frequency, short-term individual contacts, with take-
away medication for holidays. During this therapeutic ritual,
the therapist praised the patients for taking disulﬁram and
maintaining abstinence, thereby providing continuous rein-
forcement of an alcohol-free lifestyle. Regular breathalyser
tests for alcohol and random urine tests for drug abuse were
conducted. Development and training of alternative coping
skills was encouraged; there was no speciﬁc treatment element
for borderline personality disorder. In case of emergency, pa-
tients and their relatives had the possibility to contact the
clinic by day or night on any day of the week.
Table 1. Patients characteristics: sociodemographic data and characteristics and history of the addiction
Patient
Age
(years) Gender
Registered
unemployed
Living in
partnership
Alcohol
dependent
(years)
Severity of alcohol
dependence
(ICD-10 criteria)
Previous inpatient
detoxiﬁcation (n)
Longest period of
abstinence without
disulﬁram
Recent ethanol
consumption
(g/day)
A 41 Male No Yes 23 6/6 28 Few weeks 500
B 39 Female Yes No 14 5/6 11 Few weeks 150
C 51 Female No Yes 29 6/6 15 Few weeks 400
D 45 Female Yes No 25 6/6 8 Few months 240
E 47 Female Yes No 12 6/6 26 Few days 400
F 44 Female Yes No 8 4/6 3 Few months 150
G 51 Male Yes No 33 6/6 22 11 months 350
H 44 Female Yes No 20 6/6 9 Few weeks 500
Mean 45.25 20.50 5.63 15.25 336.25
SD 4.30 8.67 0.74 9.13 141.72
Table 2. Patients’ characteristics and current clinical data
Patient
Alcohol induced
somatic sequelae
Psychiatric
comorbidity (axis I)
Psychiatric
comorbidity (axis II)
Dialectic behavioural
therapy in the past Psychiatric medication
A Peptic ulcer Depression (F33) BPD (borderline type)
(F60.31)
Yes, as an outpatient Oxcarbazepine 450 mg/day
Fatty liver Cannabis abuse (F12.1)
Benzodiazepine abuse (F13.1)
TD (F17.2)
B Insulin-dependent
diabetes mellitus by
chronic pancreatitis
Bulimia (F50.2) BPD (borderline type)
(F60.31)
Multiple as an outpatient
and inpatient
Citalopram 40 mg/day
Depression (F33) Lamotrigine 125 mg/day
Benzodiazepine
dependence (F13.2)
C Polyneuropathy Depression (F33) BPD (borderline type)
(F60.31)
Yes, as an outpatient
and inpatient
Olanzapine 5 mg/day
Sedative or benzodiazepine
dependence (F13.2)
TD (F17.2)
D Pancreatitis Benzodiazepine dependence
(F13.2)
BPD (borderline type)
(F60.31)
No Quetiapine 150 mg/day
Dupuytren’s contracture
Gastritis
E Fatty liver Depression (F33) BPD (impulsive type)
(F60.30)
No Quetiapine 50 mg/day
TD (F17.2) Citalopram 20 mg/day
Trimipramine 50 mg/day
Valproate 800 mg/day
F None Depression (F33) BPD (borderline type)
(F60.31)
No Citalopram 20 mg/day
TD (F17.2)
G Fatty liver TD (F17.2) BPD (borderline type)
(F60.31)
No Mirtazapine 45mg/day
Polyneuropathy Abuse of cannabis,
cocaine, mescaline and
benzodiazepines (F19.1)
Quetiapine 300 mg/day
Escitalopram 10 mg/day
H Fatty liver Depression (F33) BPD (borderline type)
(F60.31)
No Mirtazapine 45 mg/day
Peptic ulcer Posttraumatic stress
disorder (F42.1)
Pregabalin 300 mg/day
Quetiapine 300 mg/day
Escitalopram 20 mg/day
BPD, borderline personality disorder; TD, tobacco dependence.
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Initially, we intended to observe the patients for 12 months;
however, half of them continued to attend regularly beyond
the 12 months (n = 4; 50%). Therefore, we decided to report
the full-length observation time.
Because of safety concerns, we omit the administration of a
‘test drink’ following dosing with disulﬁram. If patients re-
ported excessive sedation, we reduced the dosage or gave
disulﬁram in the evening for the ﬁrst days. The intended dos-
age of disulﬁram was 1.5 g/week because this dose seems to
be suﬃcient to cause a disulﬁram–alcohol reaction without
increasing the risk of toxicity in most patients (Ehrenreich
and Krampe, 1999; Fuller and Gordis, 2004).
Data acquisition was performed using electronic charts that
contained standardized clinical measurements including so-
ciodemographic data, addictive behaviour and history as
well as laboratory data. Our routine clinical assessment of pa-
tients’ addictive behaviour was by structured interview. Data
were generated at the beginning and at the end of the 3-week
inpatient treatment as well as within the course of the outpa-
tient aftercare. Abstinence was assessed at every visit by
alcohol breathalyser, physicians’ rating as well as patients’
self-report. Additionally, we randomly performed blood anal-
ysis for serum levels of gamma-glutamyltransferase and other
liver enzymes to detect drug-related hepatitis.
Outcome measures
The outcome measures refer to the outpatient treatment peri-
od. The primary outcome measure was time until the ﬁrst
relapse. ‘Relapse’ was deﬁned as any alcohol consumption.
Blood, urine or breath samples tested positive for alcohol as
well as self-reports of alcohol use were classiﬁed as relapse.
We deliberately did not diﬀer between so-called ‘mini-lapses’,
‘lapses’ and ‘relapses’ since their veriﬁcation mostly is insuf-
ﬁcient in an outpatient setting. Discontinuation of the therapy
without notice of removal was also deemed ‘relapse’. Second-
ary outcome measures were attendance to the outpatient
treatment, accumulated time of abstinence, and safety and tol-
erability of the treatment.
RESULTS
Baseline characteristics of the study group
The mean duration of alcohol dependence was 20.50 ± 8.67
years, the mean severity of alcohol dependence in terms of
fulﬁlled ICD-10 criteria (0–6) of alcohol addiction was 5.63 ±
0.74 and the mean amount of alcohol consumption previous to
inpatient treatment was 336.25 ± 141.72 g alcohol per day. In
summary, these characteristics indicate a clinical study sample
with a severe degree and history of alcohol dependence. For
more details, see Table 1.
The presence of one or more alcohol-related somatic dis-
eases in addition to alcohol dependence was found in seven
patients (88%). Axis I psychiatric comorbidity was present
in all patients (100%), pointing out the burden of the study
sample. The diagnosis of BPD was made by external psychia-
trists and conﬁrmed by us. A dialectic behaviour therapy
preceding the supervised disulﬁram therapy had been under-
taken in three patients (37.5%).
With regard to axis I psychiatric comorbidity, patients
mostly suﬀered from depression and/or additional substance
abuse. Tobacco dependence was found in 75% of the study
subjects. For more details, see Table 2.
The severity of addiction, sequelae of addiction and psy-
chiatric comorbidity in our sample was higher than ﬁndings
in some other clinical studies in the alcoholism ﬁeld (Anton
et al., 2006).
Safety and adverse events
There were no serious adverse events recorded in the electron-
ic patient record. No patient made a suicide threat during the
recorded treatment phase or reported self-harming. However,
we cannot exclude unreported self-harming. Tiredness during
the day was the most prominent adverse event reported in all
eight cases at the beginning of the therapy with disulﬁram and
completely disappeared in all patients within the ﬁrst 6 weeks
of the treatment. Two patients complained of headache and
three patients reported gastrointestinal adverse events; one
male patient reported sexual dysfunction.
Five of eight patients experienced mild alcohol–disulﬁram
reaction after drinking alcohol; speciﬁc inpatient or other ther-
apy was not necessary in any case. The overall tolerability and
safety of disulﬁram was considered to be good.
Alcohol drinking outcomes
Two patients remained completely abstinent under the super-
vised disulﬁram therapy over the treatment period examined
(4.5 and 14 months). Patients were highly compliant with
the treatment. Mean adherence to treatment was between
18.44 ± 21.78 months. The time elapsed before the ﬁrst al-
cohol relapse was on average 1.38 ± 1.41 months. The
cumulative alcohol abstinence achieved within the outpatient
treatment was 16.88 ± 20.48 months. The patients suﬀered
from 2.75 ± 2.96 relapses during the observation period.
DISCUSSION
Our disulﬁram treatment approach within a routine clinical
programme of alcohol dependence found that patients with
BPD had a relatively low rate of drinking days (cumulated
duration of abstinence 16.88 months), in contrast to studies
in which the presence of at least one axis II disorder predicted
a poor drinking outcome (Kranzler et al., 1996; Wolwer et al.,
2001; Krampe et al., 2006b; Hilwerling et al., 2007).
Comparing our data with that reported by Diehl et al.
(2010) from the same clinic, but across a broad spectrum of
patients, the medians of cumulated time of abstinence are sim-
ilar (10.50, conﬁdence interval (CI) 1.00–63.50 vs 9.75, CI
5.50–12.50) despite our BDP patients exhibiting a more se-
vere phenotype of alcohol dependence and suﬀering from
more comorbid psychiatric disease. Moreover, compliance
and safety of disulﬁram treatment was satisfactory in our
study. These results are in line with data published recently
by Ralevski et al. who demonstrated that the diagnosis of per-
sonality disorder did not essentially adversely aﬀect alcohol
outcomes (Ralevski et al., 2007). Patients with comorbid bor-
derline personality disorder did not have poorer response to
medication per se than patients without diagnosis of a person-
ality disorder (Ralevski et al., 2007). However, the follow-up
period in that placebo controlled trial was only 12 weeks
(Ralevski et al., 2007) compared to a mean duration of ther-
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apy of 18.44 months in our study. Despite this much longer
observation period, we did not ﬁnd a high rate of adverse
events. In particular, disulﬁram hepatotoxicity was not ob-
served since this most toxic and nickel-sensitivity-associated
adverse eﬀect is more common in women (Enghusen et al.,
1992; Chick, 1999), and our BPD patients were mainly fe-
male. Furthermore, no cases of severe alcohol disulﬁram
reaction occurred in our study, although this may reﬂect the
relatively low doses of disulﬁram used (standard treatment
dose in our study 1.5–2.5 g/week). The low rates of adverse
events have probably contributed to the good compliance and
adherence to the treatment in our study. We recognize that a
key feature for the good outcome of our eight patients might
be the combination of disulﬁram with personal contact with a
physician three times per week, which is a means to facilitate
structured, frequent therapeutic contacts that enhance self-
esteem and permits a relatively long-term stable therapeutic
relationship. This may address a key symptom of borderline
disorders, namely distress at the breaking oﬀ of relationships.
Irrespective of the psychotherapeutic eﬀects, high-frequency
contact between patient and professional is indispensable for
an up-to-date and safe treatment in every disulﬁram-treated
patient (Krampe et al., 2006a).
Krampe et al. have investigated treatment outcome of super-
vised disulﬁram therapy and found a positive association
between worse treatment outcome and the number of past ther-
apies as well as comorbid axis II disorder (Krampe et al.,
2006a).
Diehl et al. (2010) found that patients with a long history
of alcoholism addiction showed a longer time to the ﬁrst re-
lapse when treated with supervised disulﬁram than patients
treated with acamprosate. As long as there are no other spe-
ciﬁc and eﬀective pharmacological relapse prevention
therapies available, supervised disulﬁram seems to improve
alcohol drinking outcomes in patients suﬀering from comor-
bid borderline personality disorder, especially in patients
with high compliance (Neto et al., 2007). Nevertheless, we
believe that patients with acute major depression, acute suicidal
tendency and self-inﬂicted injuries should not be oﬀered disul-
ﬁram. On the other hand, we recognize that depression,
suicidal tendency and self-inﬂicted injuries are often caused
by alcohol intoxication in patients with borderline personality
disorders, and in our small study no patient threatened or actu-
ally self-harmed.
The validity of uncontrolled case observations is limited.
However, they are useful for ﬁrst assumptions about a drug’s
eﬃcacy and tolerability. In our study, we demonstrated eﬀec-
tiveness in alcohol drinking outcomes, good tolerability and
safety in patients with comorbid borderline personality disor-
der and alcohol dependence. In addition to pharmacotherapy,
it is also important to keep in mind that a combination of psy-
chosocial treatments, dialectic behaviour therapies, group
therapies and contingency management therapies are especial-
ly eﬃcient and necessary for a successful therapy of these
severely aﬀected patients.
Limitations of the study
This case series does not provide a control group. Therefore, it
cannot be stated that disulﬁram treatment is superior to stan-
dard treatment. The number of cases is low; therefore, we
cannot exclude that in other patients more or other adverse
eﬀects occur. Furthermore, our patients were treated with a
variety of other psychotropic medications that may have inﬂu-
enced the outcome. As expected, our sample consisted of
predominately females; thus, the results cannot be readily ex-
trapolated to men.
Nevertheless, the special strength of this case series is the
performance in a ‘natural’ outpatient setting with standard
support of the general health system.
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